Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABVX

Abivax ADR

Sep 06 • 04:00PM ET

12.35

Dollar change +0.07
Percentage change 0.57	%

Healthcare • Biotechnology • France • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.71	Insider Own	13.04%	Shs Outstand	62.92M	Perf Week	-2.76%
Market Cap	781.38M	Forward P/E	-	EPS next Y	-3.05	Insider Trans	0.00%	Shs Float	55.01M	Perf Month	9.68%
Income	-159.75M	PEG	-	EPS next Q	-	Inst Own	41.75%	Short Float	0.30%	Perf Quarter	-11.47%
Sales	0.00M	P/S	-	EPS this Y	21.86%	Inst Trans	-	Short Ratio	2.35	Perf Half Y	-14.83%
Book/sh	3.44	P/B	3.59	EPS next Y	-6.06%	ROA	-72.68%	Short Interest	0.17M	Perf Year	-
Cash/sh	4.56	P/C	2.71	EPS next 5Y	-	ROE	-146.20%	52W Range	7.99 - 17.02	Perf YTD	15.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.12%	ROI	-60.04%	52W High	-27.44%	Beta	-
Dividend TTM	-	Quick Ratio	4.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	54.47%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	4.08	EPS Y/Y TTM	1.23%	Oper. Margin	0.00%	RSI (14)	58.23	Volatility	4.96% 4.10%
Employees	61	Debt/Eq	0.28	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.00
Option/Short	No / Yes	LT Debt/Eq	0.23	EPS Q/Q	-17.20%	Payout	-	Rel Volume	1.08	Prev Close	12.28
Sales Surprise	1.27%	EPS Surprise	-112.72%	Sales Q/Q	-	Earnings	Sep 09 BMO	Avg Volume	70.83K	Price	12.35
SMA20	6.12%	SMA50	1.37%	SMA200	-3.59%	Trades		Volume	76,768	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-24	Initiated	Laidlaw	Buy	$48
May-20-24	Initiated	BTIG Research	Buy	$43
Apr-29-24	Initiated	Piper Sandler	Overweight	$42
Apr-29-24	Initiated	Guggenheim	Buy	$50
Nov-14-23	Initiated	Morgan Stanley	Equal-Weight	$15
Nov-14-23	Initiated	Leerink Partners	Outperform	$20

Aug-06-24 02:30AM	Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone (GlobeNewswire)
Jul-15-24 04:00PM	Abivax Provides Operational and Key Program Update (GlobeNewswire)
Jun-04-24 04:10PM	Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-08-24 02:30AM	Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 (GlobeNewswire)
May-07-24 04:00PM	Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents (GlobeNewswire)
04:00PM	Loading…
Apr-05-24 04:00PM	Abivax publishes financial reports with the French and U.S. securities regulatory agencies (GlobeNewswire)
Apr-02-24 02:30AM	Abivax reports 2023 financial results and operational update (GlobeNewswire)
Feb-13-24 02:50AM	Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO) (ACCESSWIRE)
Feb-07-24 02:30AM	Abivax appoints Ana Sharma as Vice President, Global Head of Quality (GlobeNewswire)
Feb-02-24 02:30AM	Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease (GlobeNewswire)
Jan-24-24 02:30AM	Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 (GlobeNewswire)
Jan-22-24 02:30AM	Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months (GlobeNewswire)
Jan-04-24 02:30AM	Abivax 2024 Financial Communication Calendar (GlobeNewswire)
Nov-21-23 02:30AM	Abivax announces the resumption of its liquidity contract (GlobeNewswire)
Nov-14-23 08:00AM	Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
04:15PM	Loading…
Oct-24-23 04:15PM	Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market (ACCESSWIRE) +7.90%

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVX

Abivax ADR

Upgrade your FINVIZ experience